Next Article in Journal
Arrhythmogenic Right Ventricular Cardiomyopathy: From Pathophysiology to Diagnosis and Advances in Management
Previous Article in Journal
Role of Ventricular Tachycardia Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy
 
 
Cardiogenetics is published by MDPI from Volume 10 Issue 2 (2020). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Low QRS Voltage and Atrial Fibrillation Precluding Implantation of a Subcutaneous Implantable Cardioverterdefibrillator in a Patient with Arrhythmogenic Cardiomyopathy

1
Department of Cardiology, University Heart Centre, Zurich, Switzerland
2
Department of Medicine, University Hospital Zurich, Zurich, Switzerland
*
Author to whom correspondence should be addressed.
Cardiogenetics 2017, 7(1), 7025; https://doi.org/10.4081/cardiogenetics.2017.7025
Submission received: 26 August 2017 / Revised: 26 August 2017 / Accepted: 4 November 2017 / Published: 20 December 2017

Abstract

Arrhythmogenic cardiomyopathy (AC) is a rare mostly hereditary disease, in which fibro-fatty tissue replaces cardiomyocytes. Typically, the first alterations of the disease can be encountered in the epicardium of the right ventricle in adolescent patients. From there, the disease usually progresses over time. Besides the development of heart failure, the clinical significance of the disease is determined by the predisposition to potentially lethal ventricular arrhythmias. Hence, a majority of patients with AC require an implantable cardioverter-defibrillator (ICD) to be protected from sudden cardiac death. A recently developed alternative to transvenous systems are subcutaneous ICDs (S-ICD), associated with a lower risk of device-related complications such as endocarditis since no foreign material is implanted within the heart and vascular system. In this report, we describe and discuss our experience with the implantation of a S-ICD in a patient with AC, who had low QRS voltage and persistent atrial fibrillation precluding successful S-ICD implantation, as well as the challenges encountered during subsequent transvenous lead implantation.
Keywords: Arrhythmogenic right ventricular cardiomyopathy; subcutaneous implantable cardioverter/defibrillator; arrhythmia; sudden cardiac death Arrhythmogenic right ventricular cardiomyopathy; subcutaneous implantable cardioverter/defibrillator; arrhythmia; sudden cardiac death

Share and Cite

MDPI and ACS Style

Kahr, P.C.; Steffel, J.; Breitenstein, A.; Wolber, T.; Haegeli, L.M.; Akdis, D.; Duru, F.; Brunckhorst, C.; Saguner, A.M. Low QRS Voltage and Atrial Fibrillation Precluding Implantation of a Subcutaneous Implantable Cardioverterdefibrillator in a Patient with Arrhythmogenic Cardiomyopathy. Cardiogenetics 2017, 7, 7025. https://doi.org/10.4081/cardiogenetics.2017.7025

AMA Style

Kahr PC, Steffel J, Breitenstein A, Wolber T, Haegeli LM, Akdis D, Duru F, Brunckhorst C, Saguner AM. Low QRS Voltage and Atrial Fibrillation Precluding Implantation of a Subcutaneous Implantable Cardioverterdefibrillator in a Patient with Arrhythmogenic Cardiomyopathy. Cardiogenetics. 2017; 7(1):7025. https://doi.org/10.4081/cardiogenetics.2017.7025

Chicago/Turabian Style

Kahr, Peter C., Jan Steffel, Alexander Breitenstein, Thomas Wolber, Laurent M. Haegeli, Deniz Akdis, Firat Duru, Corinna Brunckhorst, and Ardan M. Saguner. 2017. "Low QRS Voltage and Atrial Fibrillation Precluding Implantation of a Subcutaneous Implantable Cardioverterdefibrillator in a Patient with Arrhythmogenic Cardiomyopathy" Cardiogenetics 7, no. 1: 7025. https://doi.org/10.4081/cardiogenetics.2017.7025

Article Metrics

Back to TopTop